David A. Brenner, M.D.
David Brenner's Research Focus
Clinical Trials
Alpha-1 Antitrypsin Deficiency Adult Liver Study
Start Date: Dec 2013
Estimated Completion Date: Sep 2023
Recruitment Status: Recruiting
Condition(s): Alpha-1 Antitrypsin Deficiency
Research Activities and Funding
- Microbiome as Therapeutic Target in Alcoholic Hepatitis
NIHU01AA021856Jun 1, 2013 - May 31, 2019
Role: Principal Investigator - The Southern California Research Center for ALPD and Cirrhosis
NIHP50AA011999Jan 1, 1999 - Dec 31, 2023
Role: Co-Investigator - Gastroenterology Research Training
NIHT32DK007737Aug 1, 1996 - Jun 30, 2026
Role: Principal Investigator - Molecular and Cellular Pathogenesis in Alcoholism
NIHP60AA011605Dec 1, 1997 - Nov 30, 2017
Role: Co-Investigator - Molecular Mechanisms by which TNFalpha Modulates Fibrosis
NIHR01GM041804Apr 1, 1989 - Dec 31, 2014
Role: Principal Investigator - Integrated Center for InVivo Microscopy
NIHP41RR005959Sep 1, 1990 - Jun 30, 2013
Role: Co-Investigator
See more
- The Role of Inflammation and Stroma in Digestive Cancer
NIHU54CA126513Sep 30, 2006 - Sep 21, 2011
Role: Co-Investigator - Angiotensin II and NADPH Oxidase in Hepatic Fibrosis
NIHR01DK072237Sep 15, 2005 - Jun 30, 2011
Role: Principal Investigator - Hepatic Stellate Cell Activation induced by Hepatitis C Virus
NIHR01AA015055Sep 30, 2003 - Aug 31, 2009
Role: Principal Investigator - Cond. Acceptance Post-Bac. Prog. Scholarship Fund
NIHS22MD000227Sep 30, 2002 - Sep 29, 2005
Role: Principal Investigator - Molecular Pathogenesis of Apoptosis in Liver Cells
NIHP01DK059340Sep 21, 2001 - May 31, 2006
Role: Co-Investigator - Oncogenic K-Ras Induction of Gastrin Gene Transcription
NIHR01DK055686Aug 15, 2000 - Jul 31, 2006
Role: Principal Investigator - Gene Technology Therapy and Alcohol-Induced Fibrosis
NIHR01AA012586Sep 23, 1999 - Jun 30, 2003
Role: Principal Investigator - Molecular and Cellular Pathogenesis in Alcoholism
NIHP50AA011605Dec 1, 1997 - Nov 30, 2002
Role: Co-Investigator - Rat Model of Alcoholic Pancreatitis
NIHR03AA011226Apr 1, 1997 - Mar 31, 1999
Role: Principal Investigator - Gene Therapy for Liver Diseases
NIHR13DK047627Jan 20, 1994 - Oct 31, 1994
Role: Principal Investigator - Molecular Defects in Protoporphyria
NIHR01DK047361May 1, 1993 - May 31, 2004
Role: Principal Investigator - Function of Nuclear Oncogenes in Cancer Cells
NIHP01CA050528Sep 8, 1989 - Jan 31, 1998
Role: Co-Investigator - Molecular Defect in Protoporphyria
NIHR29DK039996Apr 1, 1988 - Mar 31, 1993
Role: Principal Investigator - General Clinical Research Center
NIHM01RR000827Mar 1, 1974 - Nov 30, 2010
Role: Principal Investigator
David Brenner's Bio
Dr. David A. Brenner is a distinguished physician-scientist and leader in the field of gastroenterological research and has been in practice for more than 20 years.
Education and Training
1988: Fellowship, Gastroenterology, UC San Diego
1986: Fellowship, Genetics & Biochemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
1985: Intern & Residency, Internal Medicine, Yale University
1979: M.D., Medicine, Yale University
1975: B.S., Biology, Yale University
Awards, Honors and Recognition
2005: Fellow (FACP), American College of Physicians
1986: Bomedical Scholar, Pew Foundation
Other Appointments and Memberships
Alcoholic Beverage Medical Research Foundation
American Society for Clinical Investigation
Association of American Physicians
American College of Physicians
American Gastroenterological Association
American Clinical and Climatological Association
Publications
The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury.
Nishio T, Koyama Y, Fuji H, Ishizuka K, Iwaisako K, Taura K, Hatano E, Brenner DA, Kisseleva T
Biology (Basel) 2022 Oct 28 ;11(11)
Multiplex short tandem repeat profiling of immortalized hepatic stellate cell line Col-GFP HSC.
Meurer SK, Brenner DA, Weiskirchen R
PLoS One 2022 ;17(9):e0274219
Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.
Carvalho-Gontijo R, Han C, Zhang L, Zhang V, Hosseini M, Mekeel K, Schnabl B, Loomba R, Karin M, Brenner DA, Kisseleva T
Semin Liver Dis 2022 Aug ;42(3):233-249
Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis.
Gao H, Jin Z, Bandyopadhyay G, Wang G, Zhang D, Rocha KCE, Liu X, Zhao H, Kisseleva T, Brenner DA, Karin M, Ying W
Cell Metab 2022 Aug 2 ;34(8):1201-1213.e5
MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH.
Gao H, Jin Z, Bandyopadhyay G, Cunha E Rocha K, Liu X, Zhao H, Zhang D, Jouihan H, Pourshahian S, Kisseleva T, Brenner DA, Ying W, Olefsky JM
Cell Metab 2022 Jul 5 ;34(7):978-990.e4
CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease.
Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, Papachristoforou E, Argemi J, Mendes BG, Wang Y, Su H, Sun W, Llorente C, Hendrikx T, Liu X, Hosseini M, Kisseleva T, Brenner DA, Bataller R, Ramachandran P, Karin M, Fu W, Schnabl B
Nat Commun 2021 Dec 9 ;12(1):7172
